<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PRETOMANID - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for PRETOMANID">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>PRETOMANID</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>PRETOMANID</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Pretomanid functions through a prodrug mechanism requiring activation by mycobacterial enzymes, specifically Ddn (deazaflavin-dependent nitroreductase) and Fgd1 (F420-dependent glucose-6-phosphate dehydrogenase). Pretomanid is activated by mycobacterial nitroreductases to form reactive metabolites that cause respiratory poisoning and inhibit cell wall synthesis in Mycobacterium tuberculosis. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. Pretomanid is a laboratory-produced compound belonging to the nitroimidazooxazine class of antimycobacterial agents. It was developed through rational drug design and medicinal chemistry optimization rather than isolation from natural sources. No documentation exists of its natural occurrence in plants, animals, fungi, minerals, or marine organisms. The compound is not produced via fermentation or traditional biosynthetic methods. There is no evidence of historical use in traditional medicine systems. The compound features a nitro group attached to an imidazole ring fused with an oxazine ring, along with a trifluoromethoxy-substituted benzyl side chain. This unique structural framework has no known natural analogs and works to share significant structural similarity with naturally occurring compounds or endogenous human molecules.</p>

<h3>Biological Mechanism Evaluation</h3> Pretomanid functions through a prodrug mechanism requiring activation by mycobacterial enzymes, specifically Ddn (deazaflavin-dependent nitroreductase) and Fgd1 (F420-dependent glucose-6-phosphate dehydrogenase). Upon activation, it generates reactive nitrogen species that disrupt mycobacterial respiration and cell wall synthesis. While the target organism&#x27;s enzymatic systems are naturally occurring, the compound itself works to interact with human endogenous receptors or supplement natural human substances.

<h3>Natural System Integration</h3> (Expanded Assessment) Pretomanid targets the naturally occurring F420 coenzyme system in mycobacteria, which is an evolutionarily ancient electron carrier system. The medication works by interfering with pathogen-specific metabolic pathways while having minimal direct interaction with human cellular systems. It enables the host&#x27;s natural immune system to clear infection by eliminating the pathogenic burden. The compound facilitates return to natural physiological state by addressing the underlying infectious cause rather than merely suppressing symptoms. It prevents the need for more invasive interventions and surgical procedures associated with advanced drug-resistant tuberculosis.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Pretomanid is activated by mycobacterial nitroreductases to form reactive metabolites that cause respiratory poisoning and inhibit cell wall synthesis in Mycobacterium tuberculosis. The compound specifically targets the mycobacterial F420 coenzyme system, disrupting both aerobic respiration and anaerobic metabolism. This dual action is particularly effective against dormant bacilli and biofilm-associated organisms.</p>

<h3>Clinical Utility</h3> Pretomanid is indicated for treatment of pulmonary extensively drug-resistant tuberculosis (XDR-TB) or treatment-intolerant or non-responsive multidrug-resistant tuberculosis (MDR-TB) as part of combination therapy. It represents a critical therapeutic option for patients with limited treatment alternatives. The medication is used as part of short-course regimens, typically for 6 months rather than the traditional 18-24 month treatment protocols. Safety profile shows manageable adverse effects primarily involving hepatotoxicity monitoring requirements.

<h3>Integration Potential</h3> The medication is compatible with supportive naturopathic interventions including immune system support, nutritional optimization, and hepatic support protocols. It creates a therapeutic window during which natural immune function can be restored and underlying health factors addressed. Practitioner education requirements include understanding of tuberculosis pathophysiology, drug resistance patterns, and hepatic monitoring protocols.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Pretomanid received FDA approval in August 2019 under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for treatment of drug-resistant tuberculosis. It is classified as a Qualified Infectious Disease Product (QIDP) and received Orphan Drug designation. The medication has received conditional approval from the European Medicines Agency and is included in WHO treatment guidelines for drug-resistant tuberculosis.</p>

<h3>Comparable Medications</h3> Other anti-tuberculosis medications commonly included in naturopathic formularies include isoniazid, rifampin, and ethambutol, which are also pharmaceutical compounds that target pathogen-specific systems. The precedent exists for including synthetic antimicrobials that work through pathogen-selective mechanisms while enabling natural healing processes.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>PRETOMANID</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Direct natural source</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Pretomanid is a laboratory-produced compound with no direct natural derivation. Additionally, it demonstrates significant integration with naturally occurring biological systems through its interaction with the evolutionarily conserved F420 coenzyme system in mycobacteria.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>While structurally synthetic, pretomanid targets the naturally occurring F420 coenzyme system, which is an ancient electron carrier system. The compound&#x27;s mechanism relies entirely on naturally present mycobacterial enzymes for activation and function.</p><p><strong>Biological Integration:</strong></p>

<p>The medication integrates with natural systems by targeting pathogen-specific metabolic pathways while preserving human cellular function. It enables the host&#x27;s natural immune system to clear infection through pathogen elimination rather than immune modulation.</p><p><strong>Natural System Interface:</strong></p>

<p>Pretomanid works within the naturally occurring host-pathogen interaction system. It facilitates restoration of natural physiological balance by eliminating the infectious burden that modulates normal immune and metabolic function. The compound prevents the need for more invasive surgical interventions and enables return to natural health state.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Generally well-tolerated with primary concerns related to hepatotoxicity requiring monitoring. Significantly less toxic than many alternative treatments for drug-resistant tuberculosis. Represents a less invasive alternative to surgical interventions for advanced disease.</p><p><strong>Summary of Findings:</strong></p>

<p>PRETOMANID demonstrates significant therapeutic value through integration with natural physiological systems. The medication&#x27;s immune effects work through established biological pathways, supporting the body&#x27;s inherent healing processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>DrugBank. &quot;Pretomanid&quot; DrugBank Accession Number DB11838. Updated 2024. Available at: https://go.drugbank.com/drugs/DB11838 2. FDA. &quot;PRETOMANID (pretomanid) tablets, for oral use. Prescribing Information.&quot; Initial approval August 2019. Reference ID: 4468153.</li>

<li>Hwang TJ, Dotsenko S, Jafarov A, et al. &quot;Safety and availability of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.&quot; Antimicrobial Agents and Chemotherapy. 2018;62(11):e01708-18.</li>

<li>Singh R, Manjunatha U, Boshoff HIM, et al. &quot;PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.&quot; Science. 2008;322(5906):1392-1395.</li>

<li>Manjunatha UH, Boshoff H, Dowd CS, et al. &quot;Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.&quot; Proceedings of the National Academy of Sciences. 2006;103(2):431-436.</li>

<li>WHO. &quot;WHO consolidated guidelines on drug-resistant tuberculosis treatment.&quot; World Health Organization, 2019. WHO/CDS/TB/2019.</li>

<li>7. PubChem. &quot;Pretomanid&quot; PubChem CID 9578238. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/9578238 8. Bloemberg GV, Keller PM, Stucki D, et al. &quot;Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.&quot; New England Journal of Medicine. 2015;373(20):1986-1988.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>